About Dr. Michael Mullan

 

Dr. Michael Mullan MBBS, PhD

Staff Physician, Psychiatry Service, James A. Haley Veterans’ Hospital;
President and CEO of Roskamp Institute
Director Roskamp Institute Memory Clinics
CEO of Archer Pharmaceuticals

 

 Educational Background:  LMSSA, Medicine; M.B., B.S., Medicine; MRCPsych, Psychiatry; Ph.D., Molecular Genetics - University of London, England

 Michael Mullan

Research Interests:  After graduating as a medical practitioner, Dr. Michael Mullan’s interest in research was first accommodated at the Institute of Psychiatry, London University, where he accepted a research position in molecular genetics. Subsequently, he was awarded a Mental Health Foundation Research Fellowship to retrain in molecular genetics at St. Mary’s Hospital Medical School. He was senior author on several Nature and Nature Genetics articles describing mutations in the amyloid precursor protein (APP) gene that result in early-onset Alzheimer’s disease. The discovery of the Alzheimer’s causing “Swedish” mutation in the APP gene by Dr. Mullan and his colleague Dr. Fiona Crawford, led to the development of the first animal model for Alzheimer’s disease (AD). Joining the University in Tampa in 1992, he established and directed the Roskamp Laboratories and, in 1994, was appointed to the Roskamp Endowed Chair in Biological Psychiatry. In 1998, he established the Roskamp Institute, which is dedicated to finding treatments for AD and other neuropsychiatric disorders. In 2003, the Roskamp Institute relocated to a stand-alone research facility in Sarasota, Florida, which Dr. Mullan directs. He also directs a Memory Center that conducts clinical evaluations of patients and is engaged in government and industry sponsored clinical trials. The Roskamp Institute has more than 70 scientists, students, clinicians, clinical staff and support staff pursuing greater scientific understanding of neurodegenerative and neuropsychiatric disorders. Dr. Mullan receives funding for his research from many different sources including the Veteran’s Administration, the National Institutes of Health, the Alzheimer’s Association and the Department of Defense. As a VA funded investigator since 1997, he has examined extensively the role of beta-amyloid in inflammation and determined the CD40-CD40L signaling pathways associated with AD pathogenesis. This characterization of AD pathogenic mechanisms has led to the identification of several potential therapeutic targets for AD and the Roskamp Institute drug discovery program is advancing many novel therapeutics toward clinical trials. The Roskamp Institute has conducted an Alzheimer’s clinical trial in Europe with a novel, safe therapeutic that is a lead compound from laboratory assays and shows great promise in human patients.

     Dr. Michael Mullan is a well known scientific researcher in the field of Neuropsychiatric Disorder. He is currently the director of Roskamp Institute and CEO of Archer Pharmaceuticals. He the author of several patents and key publications in the field of Alzheimer's and Cancer. Some of the patents are:

  •  US PATENT# 7,589,168 Inhibition of angiogenesis by A-.beta. peptides
  • US PATENT# 7,052,852 CD45 isoform alteration in CD4.sup.+ T cells as a potential diagnostic marker in alzheimer's disease
  • US PATENT# 6,787,318  Assay for evaluating the therapeutic effectiveness of agents in reducing Alzheimer's disease pathology
  • US PATENT# 8,067,372  Modulation of angiogenesis by A-beta peptide fragments
  • US PATENT# 7,732,467  Method for reducing amyloid deposition, amyloid neurotoxicity and microgliosis
  • US PATENT#  7,605,149 Modulation of the phospholipase A2 pathway as a therapeutic

Selected Publications:

 Paris D, Bachmeier C, Patel N, Quadros A, Volmar C, Laporte V, Ganey J, Beaulieu-Abdelahad D, Ait-Ghezala G, Crawford F and Mullan M. (2011) Selective antihypertensive dihydropyridines lower Ab accumulation by targeting both the production and the clearance of Ab across the blood brain barrier. Molecular Medicine 3-1; 17 (3-4): 149-162.

  Kennelly SP, Abdullah L, Paris D, Parrish J, Mathura V, Mullan M, Crawford F, Lawlor BA, Kenny RA. (2010) Demonstration of safety in Alzheimer’s patients for intervention with an anti-hypertensive drug, Nilvadipine: results from a 6-week open label study. International Journal of Geriatric Psychiatry (ePub October).

  Paris D, Ganey NJ, Laporte V, Patel NS, Beaulieu-Abdelahad D, Bachmeier C, March A, Ait-Ghezala G, Mullan MJ. (2010) Reduction of beta-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer's disease. J Neuroinflammation. 8;7:17.

For a complete list of publication please click here.